Bibliographic Details
Main Author:	Nelson, Scott E
Format:	Online
Language:	English
Published:	Dove Medical Press 2011
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3262389/

Observational Study of Once-Daily Insulin Detemir in People with Type 2 Diabetes Aged 75 Years or Older: A Sub-Analysis of Data from the Study of Once-Daily Levemir (SOLVE)
by: Karnieli, Eddy, et al.
Published: (2013)

Initiation of once daily insulin detemir is not associated with weight gain in patients with type 2 diabetes mellitus: results from an observational study
by: Yale, Jean-François, et al.
Published: (2013)

Clinical Characteristics of Patients Responding to Once-Daily Basal Insulin Therapy in Korean Subjects with Type 2 Diabetes
by: Song, Sun Ok, et al.
Published: (2015)

Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir: Randomized, open-label, clinical trial of efficacy and safety in patients with type 2 diabetes treated with metformin alone or in combination with sulfonylureas
by: Davies, Melanie, et al.
Published: (2013)

Insulin Detemir in the Treatment of Type 1 and Type 2 Diabetes
by: Philips, Jean-Christophe, et al.
Published: (2006)

Switching from Twice-Daily Basal Insulin Injections to Once-Daily Insulin Degludec Injection for Basal-Bolus Insulin Regimen in Japanese Patients with Type 1 Diabetes: A Pilot Study
by: Tosaka, Yuka, et al.
Published: (2015)

A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treated Patients With Type 2 Diabetes
by: Bergenstal, Richard M., et al.
Published: (2012)

Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes Mellitus
by: Porcellati, Francesca, et al.
Published: (2011)

Insulin Degludec Once-Daily in Type 2 Diabetes: Simple or Step-Wise Titration (BEGIN: Once Simple Use)
by: Philis-Tsimikas, Athena, et al.
Published: (2013)

Insulin detemir for the treatment of obese patients with type 2 diabetes
by: Hollander, Priscilla A
Published: (2012)

Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients
by: Jakobsen, Marie, et al.
Published: (2012)

Insulin lispro low mixture twice daily vs basal insulin glargine once daily and prandial insulin lispro once daily as insulin intensification strategies in patients with type 2 diabetes: A Latin American subpopulation analysis of a randomized trial
by: Barbieri, Douglas Eugenio, et al.
Published: (2015)

Glargine and detemir: Safety and efficacy profiles of the long-acting basal insulin analogs
by: Poon, Kitty, et al.
Published: (2010)

Insulin lispro low mixture twice daily vs basal insulin glargine once daily and prandial insulin lispro once daily as insulin intensification strategies in patients with type 2 diabetes: Latin American subpopulation analysis of a randomized trial
by: Rojas, Arturo, et al.
Published: (2016)

Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial
by: Tinahones, F J, et al.
Published: (2014)

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin
by: Kapitza, C, et al.
Published: (2013)

Basal Supplementation of Insulin Lispro Protamine Suspension Versus Insulin Glargine and Detemir for Type 2 Diabetes: Meta-analysis of randomized controlled trials
by: Esposito, Katherine, et al.
Published: (2012)

Comparison of a Multiple Daily Insulin Injection Regimen (Glargine or Detemir Once Daily Plus Prandial Insulin Aspart) and Continuous Subcutaneous Insulin Infusion (Aspart) in Short-Term Intensive Insulin Therapy for Poorly Controlled Type 2 Diabetes Patients
by: Lv, Wen-shan, et al.
Published: (2013)

Treatment of Type 1 and Type 2 Diabetes Mellitus with Insulin Detemir, a Long-Acting Insulin Analog
by: Young, Jason R., et al.
Published: (2010)

Clinical and financial outcomes of switching insulin glargine to insulin detemir in a veteran population with type 2 diabetes
by: Asias, Bernadette D., et al.
Published: (2015)

Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
by: Petersen, Andreas B, et al.
Published: (2013)

Insulin detemir in a twice daily insulin regimen versus a three times daily insulin regimen in the treatment of type 1 diabetes in children: A pilot randomized controlled trial
by: Ho, Josephine, et al.
Published: (2011)

Pharmacokinetics and Pharmacodynamics of Therapeutic Doses of Basal Insulins NPH, Glargine, and Detemir After 1 Week of Daily Administration at Bedtime in Type 2 Diabetic Subjects: A randomized cross-over study
by: Lucidi, Paola, et al.
Published: (2011)

Comparison of thrice daily biphasic human insulin (30/70) versus basal detemir & bolus aspart in patients with poorly controlled type 2 diabetes mellitus – A pilot study
by: Shanmugasundar, G., et al.
Published: (2012)

Response to Comment on: Bergenstal et al. A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treated Patients With Type 2 Diabetes. Diabetes Care 2012;35:2140–2147
by: Bergenstal, Richard M., et al.
Published: (2013)

Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring
by: Abe, Shinya, et al.
Published: (2011)

Development of Insulin Detemir/Insulin Aspart Cross-Reacting Antibodies Following Treatment with Insulin Detemir: 104-week Study in Children and Adolescents with Type 1 Diabetes Aged 2–16 Years
by: Thalange, Nandu, et al.
Published: (2016)

Basal Insulin Requirement Is ∼30% of the Total Daily Insulin Dose in Type 1 Diabetic Patients Who Use the Insulin Pump
by: Kuroda, Akio, et al.
Published: (2011)

Once-daily dosing of gentamicin.
by: Soper, D E
Published: (1998)

Type 2 Diabetes Mellitus Management and Body Mass Index: Experiences with Initiating Insulin Detemir in the A1chieve Study
by: Khamseh, Mohammed E., et al.
Published: (2014)

Effects of Switching from Insulin Glargine or Detemir to Insulin Degludec in Patients with Type 1 Diabetes Mellitus
by: Kusunoki, Yoshiki, et al.
Published: (2013)

Twice‐ rather than once‐daily basal insulin is associated with better glycaemic control in Type 1 diabetes mellitus 12 months after skills‐based structured education in insulin self‐management
by: Hopkinson, H. E., et al.
Published: (2015)

Comment on: Bergenstal et al. A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treated Patients With Type 2 Diabetes. Diabetes Care 2012;35:2140–2147
by: Home, Philip D.
Published: (2013)

All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine
by: Strandberg, Arto Y., et al.
Published: (2016)

Clinical Experience with Insulin Detemir in Patients with Type 2 Diabetes from the Near East Countries
by: Echtay, Akram, et al.
Published: (2013)

Evaluation of Glycemia Control Achieved by Glargine and Lispro Versus Detemir and Aspart Insulin Regimes in Type 2 Diabetics Undergoing Surgery
by: Ahmad, Mushtaq, et al.
Published: (2015)

Addition of exenatide twice daily to basal insulin for the treatment of type 2 diabetes: clinical studies and practical approaches to therapy
by: Tobin, G S, et al.
Published: (2012)

Replacement of neutral protamine Hagedorn insulin with the long‐acting insulin analogue, detemir, improves glycemic control without weight gain in basal–bolus insulin therapy in Japanese patients with type 1 diabetes
by: Hayakawa, Taro, et al.
Published: (2011)

A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes
by: Alshali, Khalid Z., et al.
Published: (2016)

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin: A 24-week, randomized, placebo-controlled comparison (GetGoal-L)
by: Riddle, Matthew C., et al.
Published: (2013)

Detemir as a once-daily basal insulin in type 2 diabetes

Similar Items